Compare AbCellera Biologics Inc (ABCL) vs Braze Inc (BRZE) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Braze (BRZE) trades at $24.40, up 2.48% on the day, with a bullish technical outlook and strong analyst support. Revenue growth accelerated to 30% year-over-year in Q1 2027, though the company remains unprofitable with a net income margin of -15.51%. Recent news highlights AI-driven product enhancements and robust customer engagement demand, contributing to positive sentiment despite recent earnings misses relative to expectations.

The investment case hinges on sustained revenue acceleration and path to profitability, supported by a 96% buy rating from analysts and a $34.78 consensus price target. Key risks include persistent losses, competitive pressures in customer engagement software, and sensitivity to enterprise marketing budgets. Upside potential exists if AI adoption drives further growth and margin improvement.